Sutro Biopharma
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 42.7m | 61.9m | 67.8m | 154m | 69.3m | 57.8m | 66.2m |
% growth | - | 45 % | 10 % | 127 % | (55 %) | (16 %) | 14 % |
EBITDA | (65.3m) | (93.1m) | (125m) | (68.0m) | (217m) | (247m) | - |
% EBITDA margin | (153 %) | (150 %) | (185 %) | (44 %) | (314 %) | (427 %) | - |
Profit | (32.1m) | (106m) | (119m) | (107m) | (228m) | (280m) | (290m) |
% profit margin | (75 %) | (171 %) | (176 %) | (69 %) | (329 %) | (484 %) | (438 %) |
EV / revenue | 23.1x | 8.9x | 2.6x | 1.3x | 4.9x | 2.5x | 4.2x |
EV / EBITDA | -15.1x | -5.9x | -1.4x | -2.9x | -1.6x | -0.6x | - |
R&D budget | 77.0m | 104m | 137m | 180m | - | - | - |
R&D % of revenue | 180 % | 169 % | 202 % | 117 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$15.0m | Series B | ||
$36.5m | Series C | ||
$16.5m | Series C | ||
$26.0m | Series D | ||
* | $85.4m | Series E | |
N/A | $85.0m Valuation: $342m 6.6x EV/LTM Revenues -24.4x EV/LTM EBITDA | IPO | |
* | N/A | $75.0m | Post IPO Equity |
* | $145m | Post IPO Equity | |
* | $140m | Post IPO Equity | |
* | N/A | $75.0m | Post IPO Equity |
Total Funding | AUD312m |
Related Content
Recent News about Sutro Biopharma
EditSutro Biopharma is a clinical-stage company that specializes in the discovery, development, and manufacturing of innovative therapeutics, primarily targeting cancer and autoimmune diseases. The company leverages precision protein engineering to create superior molecules, including antibody-drug conjugates, bispecific antibodies, and cytokine derivatives. Sutro Biopharma operates in the biotechnology sector and collaborates with major pharmaceutical companies such as Bristol Myers Squibb, Merck, EMD Serono, and Vaxcyte. The business model focuses on advancing its proprietary product candidates through clinical trials and forming strategic partnerships to co-develop and commercialize its therapies. Revenue is generated through milestone payments, licensing fees, and potential future sales of approved products.
Keywords: precision protein engineering, cancer therapeutics, autoimmune diseases, antibody-drug conjugates, bispecific antibodies, cytokine derivatives, clinical-stage, biotechnology, strategic partnerships, innovative therapeutics.